secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001835268-26-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma private placement $20.2M; Phase 1 IV rademikibart shows rapid bronchodilation; Phase 3 AD efficacy
--------------------------------------------------------------------------------

- Raised $20.2M via private placement of 6.13M shares at $3.25; led by Panacea Venture; extends cash runway into H2 2027.
- Phase 1 IV rademikibart: rapid FEV1 improvements of 200-400 mL within 15 mins in asthma/COPD, maintained through Day 29.
- Phase 3 AD study: 96.6% EASI-75, 87.1% IGA 0/1, 85.3% EASI-90 at week 52; safety comparable to placebo, low conjunctivitis.
- Phase 2 Seabreeze STAT data for acute exacerbations expected mid-2026; plans to meet FDA for Phase 3 alignment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/0001835268-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/cntb-20260329.htm
  HTML page:      https://secwatch.observer/filing/0001835268-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer